Sotera Health Company

NasdaqGS:SHC Lagerbericht

Marktkapitalisierung: US$3.6b

Sotera Health Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Sotera Health wird ein jährliches Gewinn- und Umsatzwachstum von 41% bzw. 4.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 40.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 33.6% betragen.

Wichtige Informationen

41.0%

Wachstumsrate der Gewinne

40.4%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum18.4%
Wachstumsrate der Einnahmen4.8%
Zukünftige Eigenkapitalrendite33.6%
Analystenabdeckung

Good

Zuletzt aktualisiert23 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Recent updates

Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sep 02
Sotera Health Company's (NASDAQ:SHC) P/S Still Appears To Be Reasonable

Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Jun 25
Sotera Health (NASDAQ:SHC) Takes On Some Risk With Its Use Of Debt

Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

May 30
Sotera Health Company (NASDAQ:SHC) Shares Could Be 42% Below Their Intrinsic Value Estimate

The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Mar 21
The Price Is Right For Sotera Health Company (NASDAQ:SHC) Even After Diving 29%

Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

Mar 01
Sotera Health Company Just Missed Earnings - But Analysts Have Updated Their Models

McIntyre Partnerships - Sotera Health Company: A Notable Outlier At A Discount

Feb 08

Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Feb 06
Is Sotera Health (NASDAQ:SHC) A Risky Investment?

Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Dec 28
Investors Still Aren't Entirely Convinced By Sotera Health Company's (NASDAQ:SHC) Revenues Despite 26% Price Jump

Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

Dec 11
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 33% Above Its Share Price

An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sep 10
An Intrinsic Calculation For Sotera Health Company (NASDAQ:SHC) Suggests It's 37% Undervalued

Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jun 05
Sotera Health Company (NASDAQ:SHC) Shares Could Be 24% Below Their Intrinsic Value Estimate

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Feb 13
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 34%?

Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Nov 24
Market Participants Recognise Sotera Health Company's (NASDAQ:SHC) Earnings Pushing Shares 29% Higher

Sotera Health plunges 20% after jury awards $363M against its Sterigenics unit

Sep 19

Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Sep 08
Are Investors Undervaluing Sotera Health Company (NASDAQ:SHC) By 49%?

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SHC - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20261,2351582653627
12/31/20251,1621291833157
12/31/20241,102652152447
9/30/20241,12070104282N/A
6/30/20241,0984032226N/A
3/31/20241,07755-377-172N/A
12/31/20231,04951-363-148N/A
9/30/2023991-306-381-159N/A
6/30/2023976-268-342-133N/A
3/31/2023988-26170262N/A
12/31/20221,004-23496278N/A
9/30/202299312190242N/A
6/30/2022971123127256N/A
3/31/2022956135159275N/A
12/31/2021931115179282N/A
9/30/202190736156237N/A
6/30/20218819127202N/A
3/31/2021842-26110171N/A
12/31/2020818-3967121N/A
9/30/2020795-2355109N/A
6/30/2020790-2868124N/A
3/31/2020772-2958116N/A
12/31/2019778-2192149N/A
12/31/2018746-647120N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SHCDas prognostizierte Gewinnwachstum (41% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: SHCDie Erträge des Unternehmens (41% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (15.4% pro Jahr).

Hohe Wachstumserträge: SHCEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: SHCDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: SHCDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SHCDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (33.6%)

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y